Delay of Alternative Antiviral Therapy and Poor Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Recipients of Allogeneic Stem Cell Transplant.
- Ella J Ariza-Heredia,
- Roy F Chemaly,
- Lokesh R Shahani,
- Ying Jang,
- Richard Champlin,
- Victor E Mulanovich
Transpl Int 2018 Feb 21. Epub 2018 Feb 21.
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyclovir-resistant HSV by plaque reduction test who received an HCT from 2002 through 2014. A total of 4028 HCTs were performed during the study period, and 18 of the recipients met the diagnostic criteria for acyclovir-resistant HSV. Read More